Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
We performed this study to clarify molecular mechanisms of development of Down syndrome-associated acute lymphoblastic leukemia (DS-ALL)and to find novel therapeutic targets, and obtained the following results. 1. Gene alterations in the receptor tyrosine kinase (RTK)-RAS and the CRLF2-JAK pathways were found in about 40% and 20% of Japanese DS-ALL patients, respectively, and they were mutually exclusive. It is suggested that these pathways are potential therapeutic targets. 2. Gene mutations in epigenetic regurators were found in about half of Japanese DS-ALL patients lacking both RTK-RAS and CRLF2-JAK pathway mutations. Epigenetic agents may be useful for these patients.
|